Objective Capital Partners Announced as Finalist for the Valuation Firm of The Year in the 17th Annual M&A Advisor Awards

Posted September 18, 2018 by OCP | Post a Comment

San Diego, September 14, 2018 – Objective Capital Partners, a leading middle-market M&A firm, has been nationally recognized as a Valuation Firm of the Year Award finalist by M&A Advisor for their valuation work in Life Sciences, Healthcare, and Technology.

Industry Finalists for the 17th M&A Advisor Awards were announced this week and Objective Capital Partners is a finalist for the Valuation Firm of the Year Award.

“Using valuation methods that focus on unique industry-specific factors and business models to assess a life science firm is important for making good investment decisions and portfolio management choices. It’s also valuable in preparation for partnering or M&A activities, negotiation of ownership interests, and increasing shareholder value,” says Channing D. Hamlet, Managing Director and head of OCP’s valuation practice.

“Our relentless focus and expertise in select industries, which includes the healthcare, life science and technology, combined with experience gained over more than 1,000 completed valuations, is the reason our clients repeatedly remark on our ability to uniquely meet their needs,” Mr. Hamlet said.

Objective Capital Partners’ Life Science and Healthcare Valuation Practice provides valuation advisory services to pre-revenue through growth stage life sciences and healthcare companies for capital raise, strategic partnering, and board-level strategic options analysis purposes.

Dr. David H. Crean PhD, Managing Director and leader of OCP’s Healthcare and Life Science Practice Group, says specific nuances inherent to the sector must be factored into valuations.

"Valuation analyses of companies and their products in the pharmaceutical, biotechnology and medical device fields are particularly challenging to standard methodologies used by third-party valuation firms.  There are protracted development times to reach the market, risk associated with preclinical and clinical development, and the significant capital needed to complete the lengthy approval process required by regulatory authorities around the world,” Dr. Crean said.

“Our team’s deep and relevant industry experience enables us to derive defensible valuations that are inclusive of the key value drivers, assumptions, and dynamics of the market potential for a company’s portfolio of products,” he said.

The M&A Advisor Awards were established in 2002, and they recognize leading dealmakers, firms and transactions around the world. A special Awards Gala will be hosted by The M&A Advisor on Tuesday November 6, 2018 at the New York Athletic Club to recognize the recipients.

Learn more about our services and industry focus here.



This article is provided for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC makes no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person.

Our Services

Learn about our services and how we can help you sell your business successfully.

LEARN MORE

Contact Us

San Diego Office:
3636 Nobel Dr., Suite 160
San Diego, CA 92122

Los Angeles Office:
10100 Santa Monica Blvd., Suite 300
Los Angeles, CA 90067

Trever Acers
Managing Director
858.663.8662 telephone
trever.acers@objectivecp.com

Channing Hamlet
Managing Director
858.342.4939 telephone
channing.hamlet@objectivecp.com

David H. Crean, Ph.D.
Managing Director
858.461.9490 telephone
david.crean@objectivecp.com

Jack J. Florio
Managing Director
858.864.4339 telephone
jack.florio@objectivecp.com